<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vivos Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/vivos-therapeutics-inc</link>
<description>Latest news and press releases for Vivos Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 20:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vivos-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d52778dffbe2df12144c.webp</url>
<title>Vivos Therapeutics Inc</title>
<link>https://6ix.com/company/vivos-therapeutics-inc</link>
</image>
<item>
<title>Vivos Therapeutics Reports Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-full-year-2025-financial-results</guid>
<pubDate>Wed, 15 Apr 2026 20:20:00 GMT</pubDate>
<description>Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions</description>
</item>
<item>
<title>Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-schedules-release-of-full-year-2025-financial-results-and-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-schedules-release-of-full-year-2025-financial-results-and-conference-call</guid>
<pubDate>Wed, 15 Apr 2026 12:45:00 GMT</pubDate>
<description>Call scheduled for today, Wednesday, April 15, 2026, at 5:00 pm ETLITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April</description>
</item>
<item>
<title>Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-completes-private-placement-with-existing-private-equity-investor-new-seneca-partners</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-completes-private-placement-with-existing-private-equity-investor-new-seneca-partners</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Private Placement Funds Operations as Vivos’ Medical Affiliation Model Begins to Take Hold LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos</description>
</item>
<item>
<title>Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-that-supported-professional-practices-have-achieved-in-network-status-across-multiple-commercial-health-insurers-and-medicare-in-key-nevada-market</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-that-supported-professional-practices-have-achieved-in-network-status-across-multiple-commercial-health-insurers-and-medicare-in-key-nevada-market</guid>
<pubDate>Thu, 26 Mar 2026 12:45:00 GMT</pubDate>
<description>Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to Legacy Business Model to Focus on Scaling its Medical Affiliation Distribution Model LITTLETON, Colo., March 26, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatm</description>
</item>
<item>
<title>Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/recent-study-confirms-fundamental-correlation-between-severity-of-obstructive-sleep-apnea-and-oral-anatomy</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/recent-study-confirms-fundamental-correlation-between-severity-of-obstructive-sleep-apnea-and-oral-anatomy</guid>
<pubDate>Tue, 17 Mar 2026 12:45:00 GMT</pubDate>
<description>Vivos CARE Oral Medical Devices Proven to Enhance Airways by Redeveloping Dental Arch Forms and JawsLITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health conditions, today announced that an a recent study published in the Journal of Clinical Medicine supports Vivos’ long maintained</description>
</item>
<item>
<title>Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-soundhealth-announce-collaboration-134500936</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-soundhealth-announce-collaboration-134500936</guid>
<pubDate>Thu, 05 Feb 2026 13:45:00 GMT</pubDate>
<description>Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a co</description>
</item>
<item>
<title>VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-inc-vvos-signs-133000852</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-inc-vvos-signs-133000852</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>Twelve months of national and global coverage to include long-form interviews, earned media, television commercials, iconic outdoor billboards, and accredited investor events NEW YORK CITY, NEW YORK / ACCESS Newswire / February 5, 2026 / Vivos Therapeutics, ...</description>
</item>
<item>
<title>Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-closing-exercise-223100509</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-closing-exercise-223100509</guid>
<pubDate>Tue, 20 Jan 2026 22:31:00 GMT</pubDate>
<description>LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise pri</description>
</item>
<item>
<title>Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-exercise-warrants-130000226</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-exercise-warrants-130000226</guid>
<pubDate>Fri, 16 Jan 2026 13:00:00 GMT</pubDate>
<description>LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and Februar</description>
</item>
<item>
<title>Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-grand-opening-134500054</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-grand-opening-134500054</guid>
<pubDate>Tue, 16 Dec 2025 13:45:00 GMT</pubDate>
<description>Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep SolutionsLITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased to announce the grand opening of its latest sleep testing and treatment center near Detroit i</description>
</item>
<item>
<title>Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-participate-online-fireside-223000492</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-participate-online-fireside-223000492</guid>
<pubDate>Mon, 15 Dec 2025 22:30:00 GMT</pubDate>
<description>LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that the Company’s CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat with Robert Sassoon, senior research</description>
</item>
<item>
<title>Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-significant-revenue-212000473</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-significant-revenue-212000473</guid>
<pubDate>Wed, 19 Nov 2025 21:20:00 GMT</pubDate>
<description>Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective d</description>
</item>
<item>
<title>Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-schedules-release-third-133000389</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-schedules-release-third-133000389</guid>
<pubDate>Wed, 19 Nov 2025 13:30:00 GMT</pubDate>
<description>Call scheduled for today, Wednesday, November 19, 2025, at 5:00 pm ETLITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today an</description>
</item>
<item>
<title>Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-releases-additional-clinical-123000151</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-releases-additional-clinical-123000151</guid>
<pubDate>Tue, 30 Sep 2025 12:30:00 GMT</pubDate>
<description>Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep ApneaLITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA),</description>
</item>
<item>
<title>Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-landmark-clinical-123000610</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-announces-landmark-clinical-123000610</guid>
<pubDate>Wed, 17 Sep 2025 12:30:00 GMT</pubDate>
<description>The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for children with OSALITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatmen</description>
</item>
<item>
<title>Sleep Apnea Economic Burden in U.S. Exceeds $150B Annually--Vivos' Novel Solution Can Help</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/sleep-apnea-economic-burden-u-121600928</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/sleep-apnea-economic-burden-u-121600928</guid>
<pubDate>Tue, 02 Sep 2025 12:16:00 GMT</pubDate>
<description>Obstructive sleep apnea (OSA) is wreaking havoc on individuals and healthcare systems alike, contributing to hypertension, diabetes, depression, and even stroke, while costing the U.S. economy a staggering $150 billion annually. (1-2) Despite its devastating impact, OSA remains underdiagnosed and undertreated. A recent study found untreated OSA patients incur healthcare costs averaging $19,566 per year, primarily due to inpatient care. (3)</description>
</item>
<item>
<title>Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-second-quarter-202000475</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-reports-second-quarter-202000475</guid>
<pubDate>Tue, 19 Aug 2025 20:20:00 GMT</pubDate>
<description>Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective</description>
</item>
<item>
<title>Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-schedules-release-second-123000426</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-schedules-release-second-123000426</guid>
<pubDate>Tue, 19 Aug 2025 12:30:00 GMT</pubDate>
<description>Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ETLITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today ann</description>
</item>
<item>
<title>Vivos Calls Out Medical Blind Spot: OSA's Overlooked Dangerous Symptoms</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-calls-medical-blind-spot-120300038</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-calls-medical-blind-spot-120300038</guid>
<pubDate>Thu, 07 Aug 2025 12:03:00 GMT</pubDate>
<description>Millions of people with Obstructive Sleep Apnea (OSA) remain undiagnosed, with disruptive symptoms such as night sweats, teeth grinding, resistant hypertension, and even erectile dysfunction often dismissed or misattributed. (1,2) But the truth is, these seemingly unrelated signs are SOS signals from a distressed body, begging for intervention. "Connecting the dots could change your life," says Kirk Huntsman, Chairman and CEO of Vivos Therapeutics, a leading innovator in breathing and sleep heal</description>
</item>
<item>
<title>Vivos Therapeutics Adds to Management Team to Support Expansion and Growth</title>
<link>https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-adds-management-team-124500522</link>
<guid isPermaLink="true">https://6ix.com/company/vivos-therapeutics-inc/news/vivos-therapeutics-adds-management-team-124500522</guid>
<pubDate>Wed, 30 Jul 2025 12:45:00 GMT</pubDate>
<description>Two Key Hires Add Significant Experience and Strengthen Vivos’ Ability to Scale Its Promising New Sleep Testing Center and Direct Patient Treatment OperationsLITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Op</description>
</item>
</channel>
</rss>